We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$53.6B
AUM Growth
+$2.66B
(+5.2%)
Cap. Flow
+$86.8M
Cap. Flow
% of AUM
0.16%
Top 10 Holdings %
Top 10 Hldgs %
37.17%
Holding
821
New
56
Increased
227
Reduced
258
Closed
253
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$86.2M |
| 2 |
Alcon
ALC
|
+$81.8M |
| 3 |
NVIDIA
NVDA
|
+$76M |
| 4 |
Corning
GLW
|
+$50.4M |
| 5 |
UnitedHealth
UNH
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$67.4M |
| 2 |
Factset
FDS
|
+$62M |
| 3 |
Euronet Worldwide
EEFT
|
+$42.3M |
| 4 |
Bank of America Series L
BAC.PRL
|
+$39.5M |
| 5 |
OPLN
Openlane
OPLN
|
+$31.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.75% |
| 2 | Consumer Discretionary | 17.74% |
| 3 | Financials | 11.65% |
| 4 | Healthcare | 11.2% |
| 5 | Communication Services | 10.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Penumbra
PEN
$12.8B
| $31.3M | 0.06% |
195,590
+3,276
| +2% | +$473K |
|
127
Reinsurance Group of America
RGA
$15.9B
| $31.3M | 0.06% |
200,387
-7,167
| -3% | -$1.07M |
|
128
Aaon
AAON
$7.65B
| $30.6M | 0.06% |
913,886
+239,181
| +35% | +$7.59M |
|
129
Booz Allen Hamilton
BAH
$9.02B
| $29.9M | 0.06% |
451,108
-43,352
| -9% | -$2.67M |
|
|
BKI
130
DELISTED
Black Knight, Inc. Common Stock
BKI
| $29.7M | 0.06% |
493,807
-27,844
| -5% | -$1.58M |
|
|
MIME
131
DELISTED
Mimecast Limited
MIME
| $29.6M | 0.06% |
634,173
+31,047
| +5% | +$1.48M |
|
132
Trupanion
TRUP
$1.18B
| $29.4M | 0.05% |
812,987
+36,609
| +5% | +$1.2M |
|
|
AJRD
133
DELISTED
Aerojet Rocketdyne Holdings
AJRD
| $29.3M | 0.05% |
655,540
-30,000
| -4% | -$1.12M |
|
134
Live Nation Entertainment
LYV
$42.7B
| $29.2M | 0.05% |
440,421
-64,277
| -13% | -$4.13M |
|
135
Kadant
KAI
$4.01B
| $28.6M | 0.05% |
315,370
-12,305
| -4% | -$1.11M |
|
136
Protolabs
PRLB
$2.12B
| $28.6M | 0.05% |
246,546
+9,495
| +4% | +$1.02M |
|
|
HZNP
137
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $28.5M | 0.05% |
1,185,701
+19,468
| +2% | +$494K |
|
|
GWR
138
DELISTED
Genesee & Wyoming Inc.
GWR
| $28.3M | 0.05% |
282,966
-10,391
| -4% | -$948K |
|
139
Kornit Digital
KRNT
$785M
| $28.3M | 0.05% |
892,594
+1,386
| +0.2% | +$38.2K |
|
140
Clear Channel Outdoor Holdings
CCO
$1.23B
| $27.9M | 0.05% |
+5,915,481
| New | +$30.2M |
|
141
Fox Factory Holding Corp
FOXF
$858M
| $27.8M | 0.05% |
337,132
+144,855
| +75% | +$10.7M |
|
|
AMED
142
DELISTED
Amedisys
AMED
| $27.8M | 0.05% |
228,573
+11,144
| +5% | +$1.32M |
|
143
AtriCure
ATRC
$2.06B
| $27.6M | 0.05% |
924,873
+14,636
| +2% | +$427K |
|
|
CHK.PRD
144
DELISTED
Chesapeake Energy Corp. 4.5% Cum. Cnvrtbl. Prfrd. Stock
CHK.PRD
| $27.6M | 0.05% |
1,273,115
-2,323
| -0.2% | -$128K |
|
145
Arcosa
ACA
$7.11B
| $27.3M | 0.05% |
725,370
+138,813
| +24% | +$4.75M |
|
146
Stoneridge
SRI
$210M
| $26.9M | 0.05% |
852,657
+320,520
| +60% | +$9.48M |
|
147
Popular Inc
BPOP
$11.2B
| $26.7M | 0.05% |
491,793
-26,246
| -5% | -$1.43M |
|
148
TransUnion
TRU
$15.5B
| $26.6M | 0.05% |
362,363
-20,369
| -5% | -$1.39M |
|
|
VRNT
149
DELISTED
Verint Systems
VRNT
| $26.6M | 0.05% |
972,082
+564,271
| +138% | +$17M |
|
150
Huron Consulting
HURN
$2.43B
| $26.6M | 0.05% |
527,270
+148,342
| +39% | +$7.26M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2019 Portfolio in Review
As of Q2 2019, Loomis, Sayles & Company held 821 positions worth $53.6B, up 5.2% from $50.9B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Loomis, Sayles & Company's Q2 2019 filing shows 56 new, 227 increased, 258 reduced and 253 closed positions. Its largest new stake was Alcon: 1,393,674 shares worth $86.5M. The largest sale was Novartis, an estimated $67.4M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q2 2019 buy was Alcon: 1,393,674 shares worth $86.5M.
- Loomis, Sayles & Company added most to Bristol-Myers Squibb in Q2 2019, an estimated $86.2M increase.
- Loomis, Sayles & Company's biggest Q2 2019 reduction was Novartis, cutting an estimated $67.4M.
- Loomis, Sayles & Company fully exited RingCentral in Q2 2019, selling an estimated $30.4M.
- Loomis, Sayles & Company's ten largest holdings make up 37% of its $53.6B portfolio in Q2 2019.
- Loomis, Sayles & Company opened 56 new positions and closed 253 in Q2 2019.
- Loomis, Sayles & Company's portfolio value rose 5.2% quarter-over-quarter to $53.6B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2019, filed 14 Aug 2019.